Clinical Trial Update: Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1 [NA]

View source ↗

Summary

A clinical trial from Universidad Autonoma de San Luis Potosí is evaluating intravitreal bevacizumab dosing for retinopathy of prematurity, but the trial status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinopathy of Prematurity

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Universidad Autonoma de San Luis Potosí | Conditions: Retinopathy of Prematurity | NA | Status: UNKNOWN